Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years.
Sep 20, 2024
1
23
A new study helps explain why having ApoE4—the gene variant most closely linked to Alzheimer's disease—increases the risk of neurodegeneration and white matter damage.
Sep 19, 2024
0
21
A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study published in the September 18, 2024, online issue of Neurology.
Sep 18, 2024
0
32
New research is more closely linking obesity to dementia. Higher levels of leptin, a hormone that helps maintain normal body weight, is associated with better signal-transmitting brain white matter in middle-aged adults, ...
Sep 18, 2024
0
27
For years, many people with Alzheimer's disease have been diagnosed clinically and confirmed at autopsy. Now Alzheimer's disease pathology can be identified with relatively high accuracy via a blood test that has the potential ...
Sep 18, 2024
0
0
The failure to diagnose Alzheimer's disease—the most common form of dementia in the elderly—at an early stage of molecular pathology is considered a major reason that treatments fail in clinical trials. Previous research ...
Sep 18, 2024
0
2
In landmark research, scientists at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) have reported the largest-ever genome-wide association study of dementia from all causes, revealing ...
Sep 17, 2024
0
27
Scientists have developed new potential therapies that selectively remove aggregated tau proteins, which are associated with Alzheimer's disease, and improve symptoms of neurodegeneration in mice.
Sep 13, 2024
0
125
Patients regularly show up at university hospitals with diseases so rare and specific as to be scarcely known to physicians in private practice. Primary 4-repeat tauopathies are a good example. These are diseases which are ...
Sep 12, 2024
0
2
A lack of diversity in genomic studies for dementia could limit the effectiveness of targeted therapies across underrepresented populations, finds research by UCL experts.
Sep 11, 2024
0
0
